BACKGROUND AND PURPOSE: Major depressive disorder (MDD) is characterized by recurrent depressive episodes and one of the treatment choices is antidepressants. Patients with MDD are at greater risk of developing major metabolic diseases that may in turn lead to stroke. Moreover, both depressive symptoms and taking antidepressant medications are associated with higher risk of stroke. However, whether and how clinical depression increases stroke risk remains an unanswered question. Our aim was to provide answers to this question. METHODS: A matched cohort study of 5015 subjects (1003 MDD patients and 4012 control subjects) was conducted using a nationwide database. Subjects were followed to a maximum of 9 years to determine rates of newly-developed strokes, and controls and MDD groups with different levels of antidepressant refractoriness were compared to determine the temporal relation between stroke and three major metabolic comorbidities (i.e., diabetes mellitus, hypertension and hyperlipidemia). The levels of depressive symptoms and the antidepressant medications before stroke onset were investigated. RESULTS: Patients with MDD had significantly higher rates of stroke (4.3% vs. 2.8%, p<0.05) during the follow-up. Mediation regression analyses revealed that the occurrence of stroke in the MDD subjects was significantly mediated by the development of major metabolic diseases. Greater severity of depression, but not greater use of antidepressants, preceded the occurrence of stroke. CONCLUSIONS: A clinical diagnosis of major depression leads to stroke indirectly through more intense depressive symptoms and the development of major comorbidities.
BACKGROUND AND PURPOSE: Major depressive disorder (MDD) is characterized by recurrent depressive episodes and one of the treatment choices is antidepressants. Patients with MDD are at greater risk of developing major metabolic diseases that may in turn lead to stroke. Moreover, both depressive symptoms and taking antidepressant medications are associated with higher risk of stroke. However, whether and how clinical depression increases stroke risk remains an unanswered question. Our aim was to provide answers to this question. METHODS: A matched cohort study of 5015 subjects (1003 MDDpatients and 4012 control subjects) was conducted using a nationwide database. Subjects were followed to a maximum of 9 years to determine rates of newly-developed strokes, and controls and MDD groups with different levels of antidepressant refractoriness were compared to determine the temporal relation between stroke and three major metabolic comorbidities (i.e., diabetes mellitus, hypertension and hyperlipidemia). The levels of depressive symptoms and the antidepressant medications before stroke onset were investigated. RESULTS:Patients with MDD had significantly higher rates of stroke (4.3% vs. 2.8%, p<0.05) during the follow-up. Mediation regression analyses revealed that the occurrence of stroke in the MDD subjects was significantly mediated by the development of major metabolic diseases. Greater severity of depression, but not greater use of antidepressants, preceded the occurrence of stroke. CONCLUSIONS: A clinical diagnosis of major depression leads to stroke indirectly through more intense depressive symptoms and the development of major comorbidities.
Authors: Valery L Feigin; Carlene M M Lawes; Derrick A Bennett; Suzanne L Barker-Collo; Varsha Parag Journal: Lancet Neurol Date: 2009-02-21 Impact factor: 44.182
Authors: Jordan W Smoller; Matthew Allison; Barbara B Cochrane; J David Curb; Roy H Perlis; Jennifer G Robinson; Milagros C Rosal; Nanette K Wenger; Sylvia Wassertheil-Smoller Journal: Arch Intern Med Date: 2009-12-14
Authors: Christoph U Correll; Marco Solmi; Nicola Veronese; Beatrice Bortolato; Stella Rosson; Paolo Santonastaso; Nita Thapa-Chhetri; Michele Fornaro; Davide Gallicchio; Enrico Collantoni; Giorgio Pigato; Angela Favaro; Francesco Monaco; Cristiano Kohler; Davy Vancampfort; Philip B Ward; Fiona Gaughran; André F Carvalho; Brendon Stubbs Journal: World Psychiatry Date: 2017-06 Impact factor: 49.548
Authors: Doyle M Cummings; Lesley D Lutes; J Lane Wilson; Marissa Carraway; Monika M Safford; Andrea Cherrington; D Leann Long; April P Carson; Ya Yuan; Virginia J Howard; George Howard Journal: J Gen Intern Med Date: 2022-03-01 Impact factor: 5.128
Authors: Dimitry S Davydow; Deborah A Levine; Kara Zivin; Wayne J Katon; Kenneth M Langa Journal: Psychosom Med Date: 2015 Feb-Mar Impact factor: 4.312
Authors: Paola Gilsanz; Laura D Kubzansky; Eric J Tchetgen Tchetgen; Qianyi Wang; Ichiro Kawachi; Kristen K Patton; Annette L Fitzpatrick; Willem J Kop; W T Longstreth; M Maria Glymour Journal: Stroke Date: 2016-12-06 Impact factor: 7.914
Authors: Erika Meza; Chloe W Eng; Joseph L Sáenz; Paola Gilsanz; Medellena Maria Glymour; Jacqueline M Torres Journal: J Am Geriatr Soc Date: 2020-09-02 Impact factor: 5.562